Summary

The neurological biomarkers market is witnessing substantial growth as healthcare systems worldwide increasingly emphasize early diagnosis and targeted treatment of neurological conditions. Biomarkers serve as measurable indicators of biological processes, enabling clinicians to detect and monitor diseases affecting the brain and nervous system with greater precision. Rising cases of neurodegenerative disorders, coupled with advancements in diagnostic technologies, are fueling demand for reliable biomarker-based solutions. The market is anticipated to reach US$ 9.4 billion in 2026 and expand to US$ 18.6 billion by 2033, progressing at a CAGR of 10.20% over the forecast period.

Market Insights

Neurological biomarkers are transforming clinical practices by improving the detection and management of complex neurological disorders such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. The integration of biomarker testing with advanced imaging techniques and molecular diagnostics is enabling more accurate and earlier diagnoses. This is particularly critical in conditions where symptoms often appear at advanced stages, limiting treatment effectiveness.

Growing investments in biomedical research and the expansion of precision medicine initiatives are contributing to the discovery of novel biomarkers. Technologies such as proteomics, genomics, and metabolomics are playing a pivotal role in identifying disease-specific indicators, allowing healthcare professionals to better understand disease progression. Additionally, collaborations between research institutions and pharmaceutical companies are accelerating the development and commercialization of innovative diagnostic tools.

Market Drivers

The increasing prevalence of neurological disorders remains a key factor driving the growth of the neurological biomarkers market. Aging populations, particularly in developed economies, are more susceptible to neurodegenerative conditions, thereby increasing the need for early and accurate diagnostic solutions. Biomarkers provide valuable insights into disease mechanisms, supporting timely interventions and improved patient outcomes.

Technological advancements in molecular biology and diagnostic platforms are further propelling market growth. The development of minimally invasive testing methods, including blood-based biomarkers, is enhancing patient comfort and expanding the adoption of these diagnostics. Additionally, the growing use of biomarkers in clinical trials is streamlining drug development by enabling patient stratification and monitoring therapeutic responses.

Another significant driver is the increasing focus on personalized medicine, where treatments are tailored to individual patient profiles. Biomarkers play a crucial role in this approach by providing detailed information about disease characteristics, enabling more effective and targeted therapies.

Business Opportunity

The neurological biomarkers market offers significant opportunities for industry participants, particularly in the development of innovative diagnostic technologies. Companies investing in advanced analytical tools and artificial intelligence are gaining a competitive edge by improving the accuracy and efficiency of biomarker analysis. The integration of AI with biomarker research is expected to accelerate discovery processes and enhance clinical applications.

Emerging economies present untapped growth potential due to improving healthcare infrastructure and rising awareness of neurological disorders. As governments in these regions increase healthcare spending and prioritize early diagnosis, demand for biomarker-based diagnostics is expected to rise significantly.

Moreover, the growing adoption of digital health solutions is opening new avenues for market expansion. The combination of biomarker data with digital monitoring tools can provide continuous insights into patient health, enabling proactive disease management and better clinical outcomes.

Region Analysis

North America holds a dominant position in the neurological biomarkers market, supported by advanced healthcare systems, strong research capabilities, and the presence of leading industry players. The region benefits from high healthcare expenditure and a favorable regulatory environment that encourages innovation.

Europe represents another significant market, driven by increasing government support for neurological research and a strong focus on early disease detection. The region’s healthcare systems are increasingly adopting biomarker-based diagnostics to improve patient care and reduce long-term healthcare costs.

Asia Pacific is projected to experience the fastest growth during the forecast period. Rapid urbanization, expanding healthcare infrastructure, and a growing patient population are key factors contributing to market expansion in this region. Countries such as China, India, and Japan are investing heavily in healthcare innovation, creating opportunities for biomarker adoption.

Latin America and the Middle East & Africa are gradually emerging as important markets, supported by improving access to healthcare services and increasing awareness about neurological conditions. Although these regions currently account for a smaller share, they offer considerable growth prospects in the coming years.

Key Players

The competitive landscape of the neurological biomarkers market is characterized by the presence of several prominent companies focusing on research, innovation, and strategic partnerships. Key players include:

• Thermo Fisher Scientific Inc.

• Abbott Laboratories

• QIAGEN N.V.

• Bio-Rad Laboratories, Inc.

• Merck KGaA

• F. Hoffmann-La Roche Ltd.

• Bio-Techne Corporation

• Quanterix Corporation

• Myriad Genetics, Inc.

• Banyan Biomarkers, Inc.

• C2N Diagnostics

• Charles River Laboratories International, Inc.

• Euroimmun AG

• Alector Inc.

• PerkinElmer Inc.

These companies are actively expanding their product portfolios and investing in advanced technologies to strengthen their market presence and meet the growing demand for neurological diagnostics.

Segmentation

By Biomarkers Type

• Proteomic Biomarkers

• Genomic Biomarkers

• Neuroimaging Biomarkers

• Metabolomics Biomarkers

By Sample

• Blood

• Plasma

• Cerebrospinal Fluid

• Others

By Indication

• Alzheimer's disease (AD)

• Multiple sclerosis (MS)

• Parkinson's disease (PD)

• Autism spectrum disorder (ASD)

• Others

By End-user

• Hospital Labs

• Diagnostic Centers

• Academic & Research Institutes

• Biopharma Companies

• Proteomic Laboratory

• Others

By Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Neurological Biomarkers Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2026
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. COVID-19 Impact Analysis
2.5. Porter's Five Forces Analysis
2.6. Impact of Russia-Ukraine Conflict
2.7. PESTLE Analysis
2.8. Regulatory Analysis
2.9. Price Trend Analysis
2.9.1. Current Prices and Future Projections, 2025-2033
2.9.2. Price Impact Factors
3. Global Neurological Biomarkers Market Outlook, 2020 - 2033
3.1. Global Neurological Biomarkers Market Outlook, by Biomarkers Type, Value (US$ Bn), 2020-2033
3.1.1. Proteomic Biomarkers
3.1.2. Genomic Biomarkers
3.1.3. Neuroimaging Biomarkers
3.1.4. Metabolomics Biomarkers
3.2. Global Neurological Biomarkers Market Outlook, by Sample, Value (US$ Bn), 2020-2033
3.2.1. Blood
3.2.2. Plasma
3.2.3. Cerebrospinal Fluid
3.2.4. Others
3.3. Global Neurological Biomarkers Market Outlook, by Indication, Value (US$ Bn), 2020-2033
3.3.1. Alzheimer's disease (AD)
3.3.2. Multiple sclerosis (MS)
3.3.3. Parkinson's disease (PD)
3.3.4. Autism spectrum disorder (ASD)
3.3.5. Others
3.4. Global Neurological Biomarkers Market Outlook, by End-user, Value (US$ Bn), 2020-2033
3.4.1. Hospital Labs
3.4.2. Diagnostic Centers
3.4.3. Academic & Research Institutes
3.4.4. Biopharma Companies
3.4.5. Proteomic Laboratory
3.4.6. Others
3.5. Global Neurological Biomarkers Market Outlook, by Region, Value (US$ Bn), 2020-2033
3.5.1. North America
3.5.2. Europe
3.5.3. Asia Pacific
3.5.4. Latin America
3.5.5. Middle East & Africa
4. North America Neurological Biomarkers Market Outlook, 2020 - 2033
4.1. North America Neurological Biomarkers Market Outlook, by Biomarkers Type, Value (US$ Bn), 2020-2033
4.1.1. Proteomic Biomarkers
4.1.2. Genomic Biomarkers
4.1.3. Neuroimaging Biomarkers
4.1.4. Metabolomics Biomarkers
4.2. North America Neurological Biomarkers Market Outlook, by Sample, Value (US$ Bn), 2020-2033
4.2.1. Blood
4.2.2. Plasma
4.2.3. Cerebrospinal Fluid
4.2.4. Others
4.3. North America Neurological Biomarkers Market Outlook, by Indication, Value (US$ Bn), 2020-2033
4.3.1. Alzheimer's disease (AD)
4.3.2. Multiple sclerosis (MS)
4.3.3. Parkinson's disease (PD)
4.3.4. Autism spectrum disorder (ASD)
4.3.5. Others
4.4. North America Neurological Biomarkers Market Outlook, by End-user, Value (US$ Bn), 2020-2033
4.4.1. Hospital Labs
4.4.2. Diagnostic Centers
4.4.3. Academic & Research Institutes
4.4.4. Biopharma Companies
4.4.5. Proteomic Laboratory
4.4.6. Others
4.5. North America Neurological Biomarkers Market Outlook, by Country, Value (US$ Bn), 2020-2033
4.5.1. U.S. Neurological Biomarkers Market Outlook, by Biomarkers Type, 2020-2033
4.5.2. U.S. Neurological Biomarkers Market Outlook, by Sample, 2020-2033
4.5.3. U.S. Neurological Biomarkers Market Outlook, by Indication, 2020-2033
4.5.4. U.S. Neurological Biomarkers Market Outlook, by End-user, 2020-2033
4.5.5. Canada Neurological Biomarkers Market Outlook, by Biomarkers Type, 2020-2033
4.5.6. Canada Neurological Biomarkers Market Outlook, by Sample, 2020-2033
4.5.7. Canada Neurological Biomarkers Market Outlook, by Indication, 2020-2033
4.5.8. Canada Neurological Biomarkers Market Outlook, by End-user, 2020-2033
4.6. BPS Analysis/Market Attractiveness Analysis
5. Europe Neurological Biomarkers Market Outlook, 2020 - 2033
5.1. Europe Neurological Biomarkers Market Outlook, by Biomarkers Type, Value (US$ Bn), 2020-2033
5.1.1. Proteomic Biomarkers
5.1.2. Genomic Biomarkers
5.1.3. Neuroimaging Biomarkers
5.1.4. Metabolomics Biomarkers
5.2. Europe Neurological Biomarkers Market Outlook, by Sample, Value (US$ Bn), 2020-2033
5.2.1. Blood
5.2.2. Plasma
5.2.3. Cerebrospinal Fluid
5.2.4. Others
5.3. Europe Neurological Biomarkers Market Outlook, by Indication, Value (US$ Bn), 2020-2033
5.3.1. Alzheimer's disease (AD)
5.3.2. Multiple sclerosis (MS)
5.3.3. Parkinson's disease (PD)
5.3.4. Autism spectrum disorder (ASD)
5.3.5. Others
5.4. Europe Neurological Biomarkers Market Outlook, by End-user, Value (US$ Bn), 2020-2033
5.4.1. Hospital Labs
5.4.2. Diagnostic Centers
5.4.3. Academic & Research Institutes
5.4.4. Biopharma Companies
5.4.5. Proteomic Laboratory
5.4.6. Others
5.5. Europe Neurological Biomarkers Market Outlook, by Country, Value (US$ Bn), 2020-2033
5.5.1. Germany Neurological Biomarkers Market Outlook, by Biomarkers Type, 2020-2033
5.5.2. Germany Neurological Biomarkers Market Outlook, by Sample, 2020-2033
5.5.3. Germany Neurological Biomarkers Market Outlook, by Indication, 2020-2033
5.5.4. Germany Neurological Biomarkers Market Outlook, by End-user, 2020-2033
5.5.5. Italy Neurological Biomarkers Market Outlook, by Biomarkers Type, 2020-2033
5.5.6. Italy Neurological Biomarkers Market Outlook, by Sample, 2020-2033
5.5.7. Italy Neurological Biomarkers Market Outlook, by Indication, 2020-2033
5.5.8. Italy Neurological Biomarkers Market Outlook, by End-user, 2020-2033
5.5.9. France Neurological Biomarkers Market Outlook, by Biomarkers Type, 2020-2033
5.5.10. France Neurological Biomarkers Market Outlook, by Sample, 2020-2033
5.5.11. France Neurological Biomarkers Market Outlook, by Indication, 2020-2033
5.5.12. France Neurological Biomarkers Market Outlook, by End-user, 2020-2033
5.5.13. U.K. Neurological Biomarkers Market Outlook, by Biomarkers Type, 2020-2033
5.5.14. U.K. Neurological Biomarkers Market Outlook, by Sample, 2020-2033
5.5.15. U.K. Neurological Biomarkers Market Outlook, by Indication, 2020-2033
5.5.16. U.K. Neurological Biomarkers Market Outlook, by End-user, 2020-2033
5.5.17. Spain Neurological Biomarkers Market Outlook, by Biomarkers Type, 2020-2033
5.5.18. Spain Neurological Biomarkers Market Outlook, by Sample, 2020-2033
5.5.19. Spain Neurological Biomarkers Market Outlook, by Indication, 2020-2033
5.5.20. Spain Neurological Biomarkers Market Outlook, by End-user, 2020-2033
5.5.21. Russia Neurological Biomarkers Market Outlook, by Biomarkers Type, 2020-2033
5.5.22. Russia Neurological Biomarkers Market Outlook, by Sample, 2020-2033
5.5.23. Russia Neurological Biomarkers Market Outlook, by Indication, 2020-2033
5.5.24. Russia Neurological Biomarkers Market Outlook, by End-user, 2020-2033
5.5.25. Rest of Europe Neurological Biomarkers Market Outlook, by Biomarkers Type, 2020-2033
5.5.26. Rest of Europe Neurological Biomarkers Market Outlook, by Sample, 2020-2033
5.5.27. Rest of Europe Neurological Biomarkers Market Outlook, by Indication, 2020-2033
5.5.28. Rest of Europe Neurological Biomarkers Market Outlook, by End-user, 2020-2033
5.6. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Neurological Biomarkers Market Outlook, 2020 - 2033
6.1. Asia Pacific Neurological Biomarkers Market Outlook, by Biomarkers Type, Value (US$ Bn), 2020-2033
6.1.1. Proteomic Biomarkers
6.1.2. Genomic Biomarkers
6.1.3. Neuroimaging Biomarkers
6.1.4. Metabolomics Biomarkers
6.2. Asia Pacific Neurological Biomarkers Market Outlook, by Sample, Value (US$ Bn), 2020-2033
6.2.1. Blood
6.2.2. Plasma
6.2.3. Cerebrospinal Fluid
6.2.4. Others
6.3. Asia Pacific Neurological Biomarkers Market Outlook, by Indication, Value (US$ Bn), 2020-2033
6.3.1. Alzheimer's disease (AD)
6.3.2. Multiple sclerosis (MS)
6.3.3. Parkinson's disease (PD)
6.3.4. Autism spectrum disorder (ASD)
6.3.5. Others
6.4. Asia Pacific Neurological Biomarkers Market Outlook, by End-user, Value (US$ Bn), 2020-2033
6.4.1. Hospital Labs
6.4.2. Diagnostic Centers
6.4.3. Academic & Research Institutes
6.4.4. Biopharma Companies
6.4.5. Proteomic Laboratory
6.4.6. Others
6.5. Asia Pacific Neurological Biomarkers Market Outlook, by Country, Value (US$ Bn), 2020-2033
6.5.1. China Neurological Biomarkers Market Outlook, by Biomarkers Type, 2020-2033
6.5.2. China Neurological Biomarkers Market Outlook, by Sample, 2020-2033
6.5.3. China Neurological Biomarkers Market Outlook, by Indication, 2020-2033
6.5.4. China Neurological Biomarkers Market Outlook, by End-user, 2020-2033
6.5.5. Japan Neurological Biomarkers Market Outlook, by Biomarkers Type, 2020-2033
6.5.6. Japan Neurological Biomarkers Market Outlook, by Sample, 2020-2033
6.5.7. Japan Neurological Biomarkers Market Outlook, by Indication, 2020-2033
6.5.8. Japan Neurological Biomarkers Market Outlook, by End-user, 2020-2033
6.5.9. South Korea Neurological Biomarkers Market Outlook, by Biomarkers Type, 2020-2033
6.5.10. South Korea Neurological Biomarkers Market Outlook, by Sample, 2020-2033
6.5.11. South Korea Neurological Biomarkers Market Outlook, by Indication, 2020-2033
6.5.12. South Korea Neurological Biomarkers Market Outlook, by End-user, 2020-2033
6.5.13. India Neurological Biomarkers Market Outlook, by Biomarkers Type, 2020-2033
6.5.14. India Neurological Biomarkers Market Outlook, by Sample, 2020-2033
6.5.15. India Neurological Biomarkers Market Outlook, by Indication, 2020-2033
6.5.16. India Neurological Biomarkers Market Outlook, by End-user, 2020-2033
6.5.17. Southeast Asia Neurological Biomarkers Market Outlook, by Biomarkers Type, 2020-2033
6.5.18. Southeast Asia Neurological Biomarkers Market Outlook, by Sample, 2020-2033
6.5.19. Southeast Asia Neurological Biomarkers Market Outlook, by Indication, 2020-2033
6.5.20. Southeast Asia Neurological Biomarkers Market Outlook, by End-user, 2020-2033
6.5.21. Rest of SAO Neurological Biomarkers Market Outlook, by Biomarkers Type, 2020-2033
6.5.22. Rest of SAO Neurological Biomarkers Market Outlook, by Sample, 2020-2033
6.5.23. Rest of SAO Neurological Biomarkers Market Outlook, by Indication, 2020-2033
6.5.24. Rest of SAO Neurological Biomarkers Market Outlook, by End-user, 2020-2033
6.6. BPS Analysis/Market Attractiveness Analysis
7. Latin America Neurological Biomarkers Market Outlook, 2020 - 2033
7.1. Latin America Neurological Biomarkers Market Outlook, by Biomarkers Type, Value (US$ Bn), 2020-2033
7.1.1. Proteomic Biomarkers
7.1.2. Genomic Biomarkers
7.1.3. Neuroimaging Biomarkers
7.1.4. Metabolomics Biomarkers
7.2. Latin America Neurological Biomarkers Market Outlook, by Sample, Value (US$ Bn), 2020-2033
7.2.1. Blood
7.2.2. Plasma
7.2.3. Cerebrospinal Fluid
7.2.4. Others
7.3. Latin America Neurological Biomarkers Market Outlook, by Indication, Value (US$ Bn), 2020-2033
7.3.1. Alzheimer's disease (AD)
7.3.2. Multiple sclerosis (MS)
7.3.3. Parkinson's disease (PD)
7.3.4. Autism spectrum disorder (ASD)
7.3.5. Others
7.4. Latin America Neurological Biomarkers Market Outlook, by End-user, Value (US$ Bn), 2020-2033
7.4.1. Hospital Labs
7.4.2. Diagnostic Centers
7.4.3. Academic & Research Institutes
7.4.4. Biopharma Companies
7.4.5. Proteomic Laboratory
7.4.6. Others
7.5. Latin America Neurological Biomarkers Market Outlook, by Country, Value (US$ Bn), 2020-2033
7.5.1. Brazil Neurological Biomarkers Market Outlook, by Biomarkers Type, 2020-2033
7.5.2. Brazil Neurological Biomarkers Market Outlook, by Sample, 2020-2033
7.5.3. Brazil Neurological Biomarkers Market Outlook, by Indication, 2020-2033
7.5.4. Brazil Neurological Biomarkers Market Outlook, by End-user, 2020-2033
7.5.5. Mexico Neurological Biomarkers Market Outlook, by Biomarkers Type, 2020-2033
7.5.6. Mexico Neurological Biomarkers Market Outlook, by Sample, 2020-2033
7.5.7. Mexico Neurological Biomarkers Market Outlook, by Indication, 2020-2033
7.5.8. Mexico Neurological Biomarkers Market Outlook, by End-user, 2020-2033
7.5.9. Argentina Neurological Biomarkers Market Outlook, by Biomarkers Type, 2020-2033
7.5.10. Argentina Neurological Biomarkers Market Outlook, by Sample, 2020-2033
7.5.11. Argentina Neurological Biomarkers Market Outlook, by Indication, 2020-2033
7.5.12. Argentina Neurological Biomarkers Market Outlook, by End-user, 2020-2033
7.5.13. Rest of LATAM Neurological Biomarkers Market Outlook, by Biomarkers Type, 2020-2033
7.5.14. Rest of LATAM Neurological Biomarkers Market Outlook, by Sample, 2020-2033
7.5.15. Rest of LATAM Neurological Biomarkers Market Outlook, by Indication, 2020-2033
7.5.16. Rest of LATAM Neurological Biomarkers Market Outlook, by End-user, 2020-2033
7.6. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Neurological Biomarkers Market Outlook, 2020 - 2033
8.1. Middle East & Africa Neurological Biomarkers Market Outlook, by Biomarkers Type, Value (US$ Bn), 2020-2033
8.1.1. Proteomic Biomarkers
8.1.2. Genomic Biomarkers
8.1.3. Neuroimaging Biomarkers
8.1.4. Metabolomics Biomarkers
8.2. Middle East & Africa Neurological Biomarkers Market Outlook, by Sample, Value (US$ Bn), 2020-2033
8.2.1. Blood
8.2.2. Plasma
8.2.3. Cerebrospinal Fluid
8.2.4. Others
8.3. Middle East & Africa Neurological Biomarkers Market Outlook, by Indication, Value (US$ Bn), 2020-2033
8.3.1. Alzheimer's disease (AD)
8.3.2. Multiple sclerosis (MS)
8.3.3. Parkinson's disease (PD)
8.3.4. Autism spectrum disorder (ASD)
8.3.5. Others
8.4. Middle East & Africa Neurological Biomarkers Market Outlook, by End-user, Value (US$ Bn), 2020-2033
8.4.1. Hospital Labs
8.4.2. Diagnostic Centers
8.4.3. Academic & Research Institutes
8.4.4. Biopharma Companies
8.4.5. Proteomic Laboratory
8.4.6. Others
8.5. Middle East & Africa Neurological Biomarkers Market Outlook, by Country, Value (US$ Bn), 2020-2033
8.5.1. GCC Neurological Biomarkers Market Outlook, by Biomarkers Type, 2020-2033
8.5.2. GCC Neurological Biomarkers Market Outlook, by Sample, 2020-2033
8.5.3. GCC Neurological Biomarkers Market Outlook, by Indication, 2020-2033
8.5.4. GCC Neurological Biomarkers Market Outlook, by End-user, 2020-2033
8.5.5. South Africa Neurological Biomarkers Market Outlook, by Biomarkers Type, 2020-2033
8.5.6. South Africa Neurological Biomarkers Market Outlook, by Sample, 2020-2033
8.5.7. South Africa Neurological Biomarkers Market Outlook, by Indication, 2020-2033
8.5.8. South Africa Neurological Biomarkers Market Outlook, by End-user, 2020-2033
8.5.9. Egypt Neurological Biomarkers Market Outlook, by Biomarkers Type, 2020-2033
8.5.10. Egypt Neurological Biomarkers Market Outlook, by Sample, 2020-2033
8.5.11. Egypt Neurological Biomarkers Market Outlook, by Indication, 2020-2033
8.5.12. Egypt Neurological Biomarkers Market Outlook, by End-user, 2020-2033
8.5.13. Nigeria Neurological Biomarkers Market Outlook, by Biomarkers Type, 2020-2033
8.5.14. Nigeria Neurological Biomarkers Market Outlook, by Sample, 2020-2033
8.5.15. Nigeria Neurological Biomarkers Market Outlook, by Indication, 2020-2033
8.5.16. Nigeria Neurological Biomarkers Market Outlook, by End-user, 2020-2033
8.5.17. Rest of Middle East Neurological Biomarkers Market Outlook, by Biomarkers Type, 2020-2033
8.5.18. Rest of Middle East Neurological Biomarkers Market Outlook, by Sample, 2020-2033
8.5.19. Rest of Middle East Neurological Biomarkers Market Outlook, by Indication, 2020-2033
8.5.20. Rest of Middle East Neurological Biomarkers Market Outlook, by End-user, 2020-2033
8.6. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Vs Segment Heatmap
9.2. Company Market Share Analysis, 2025
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Thermo Fisher Scientific Inc.
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Developments
9.4.2. Abbott Laboratories
9.4.3. QIAGEN N.V.
9.4.4. Bio-Rad Laboratories, Inc.
9.4.5. Merck KGaA
9.4.6. F. Hoffmann-La Roche Ltd.
9.4.7. Bio-Techne Corporation
9.4.8. Quanterix Corporation
9.4.9. Myriad Genetics, Inc.
9.4.10. Banyan Biomarkers, Inc.
9.4.11. C2N Diagnostics
9.4.12. Charles River Laboratories International, Inc.
9.4.13. Euroimmun AG
9.4.14. Alector Inc.
9.4.15. PerkinElmer Inc.
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations